Skip to main content

Faecal Incontinence

4
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Norgine
NorgineAustria - Vienna
3 programs
2
1
1R, 2S-methoxamine hydrochloridePhase 21 trial
NRL001 cream 0.5%w/wPhase 11 trial
Perianal NRL001 Gel 3 strengthsPhase 11 trial
Active Trials
NCT06593730Completed72Est. Sep 2007
NCT06593743Completed44Est. Nov 2013
NCT01656720Completed417Est. Sep 2014
Design Pharmaceuticals
1 program
1
Infusion of mesenchymal stem cells from adipose tissuePhase 1/21 trial
Active Trials
NCT02292628Completed16Est. Sep 2017
Coloplast
ColoplastAustralia - Mulgrave
1 program
Peristeen Light - trans anal irrigation systemN/A1 trial
Active Trials
NCT07126327Recruiting60Est. Aug 2026
Design Therapeutics
1 program
Infusion of mesenchymal stem cells from adipose tissuePHASE_1_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Norgine1R, 2S-methoxamine hydrochloride
Design PharmaceuticalsInfusion of mesenchymal stem cells from adipose tissue
NorgineNRL001 cream 0.5%w/w
NorginePerianal NRL001 Gel 3 strengths
ColoplastPeristeen Light - trans anal irrigation system

Clinical Trials (5)

Total enrollment: 609 patients across 5 trials

NCT01656720Norgine1R, 2S-methoxamine hydrochloride

A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period

Start: Feb 2012Est. completion: Sep 2014417 patients
Phase 2Completed
NCT02292628Design PharmaceuticalsInfusion of mesenchymal stem cells from adipose tissue

Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence

Start: Oct 2013Est. completion: Sep 201716 patients
Phase 1/2Completed
NCT06593730NorgineNRL001 cream 0.5%w/w

Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 Days

Start: Aug 2007Est. completion: Sep 200772 patients
Phase 1Completed
NCT06593743NorginePerianal NRL001 Gel 3 strengths

The Safety and Dose Response to Single Anal Doses of NRL001

Start: Dec 2002Est. completion: Nov 201344 patients
Phase 1Completed
NCT07126327ColoplastPeristeen Light - trans anal irrigation system

Peristeen Light Explorative Clinical Investigation

Start: Nov 2025Est. completion: Aug 202660 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 609 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.